Chronic obstructive pulmonary disease (COPD) is a complex chronic condition, characterised by exacerbations that have an impact on the disease progression and patients’ quality of life.
In this context, EFA has joined the “Combining Artificial Intelligence and smart sensing TOward better management and improved quality of LIFE in chronic obstructive pulmonary disease” (TOLIFE) project. This new project aims to develop a clinically validated Artificial Intelligence (AI)-based platform to predict early exacerbations of the disease, and be the base to optimise personalised treatment, assess health outcomes, and improve quality of life.
EFA will be responsible of the creation, recruitment, and implementation of a Patient Advisory Group (PAG), formed by at least 10 COPD patients. This group will see that TOLIFE operates with a patient-centric approach which ensures the COPD management models will address patients’ needs, be understandable for its lay target group, and will deliver specific outcomes with the potential to improve the lives of COPD patients. EFA will facilitate the discussion between patients experts and researchers and oversee the feedbacks and indications of both patients and caregivers concerning the invasiveness, privacy impact, usefulness and safety perceived of the technology.
TOLIFE is funded by the Horizon Europe Framework Programme (HORIZON) and has started on 1st September 2022 with a duration of 54 months.